Targeting Macrophages in Immunotherapy: The Ascent of CAR-Macrophages
International Journal of Molecular Sciences · 28.01.2026 · 27 (3) · 1292
DOI: 10.3390/ijms27031292 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift International Journal of Molecular Sciences, online erschienen am 28.01.2026. Verfasst von Vinod Nadella und 1 weiteren Autor:innen. Beteiligte Einrichtung: Department of Host Microbe Interactions, St. Jude Children's Research Hospital, Memphis, TN 38103, USA. Hauptthemen laut MEDLINE: Receptors, Chimeric Antigen, Macrophages, Neoplasms, Immunotherapy, Adoptive. Die Arbeit wurde bisher 7-mal zitiert (Crossref) und nennt 76 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Chimeric antigen receptor (CAR)-engineered immune cell therapies have revolutionized cancer treatment, with CAR-T cells demonstrating remarkable efficacy against hematological malignancies. However, the effectiveness of CAR-T and other lymphocyte-based therapies against solid tumors remains limited, primarily due to the immunosuppressive tumor microenvironment and poor infiltration of effector cells. Recently, CAR-macrophage (CAR-M) immunotherapy has emerged as a promising strategy to overcome these barriers. Leveraging the innate tumor-homing ability, phagocytic function, and antigen-presenting capacity of macrophages, CAR-M therapies offer unique advantages for targeting solid tumors. This review provides a comprehensive overview of the development and current state of CAR-Macrophage immunotherapy, including advances in CAR design and macrophage engineering, preclinical and clinical progress, and mechanistic insights into their anti-tumor activity. The review critically examined both the benefits and limitations of CAR-M approaches, addressing persistent challenges such as cell sourcing, durability, and safety, while also exploring innovative strategies to enhance therapeutic efficacy. Finally, future perspectives and the potential clinical impact of CAR-macrophage therapies were outlined, underscoring their emerging role in the evolving landscape of cancer immunotherapy.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Host Microbe Interactions, St. Jude Children's Research Hospital, Memphis, TN 38103, USA.
- Department of Oncology, St. Jude Children's Research Hospital, Memphis, TN 38103, USA.
ORCID-Profile: Vinod Nadella
Zitieren
APA
Nadella, V., & Sharma, A. (2026). Targeting Macrophages in Immunotherapy: The Ascent of CAR-Macrophages. International Journal of Molecular Sciences, 27(3), 1292. https://doi.org/10.3390/ijms27031292
Vancouver
Nadella V, Sharma A. Targeting Macrophages in Immunotherapy: The Ascent of CAR-Macrophages. International Journal of Molecular Sciences. 2026;27(3):1292. doi:10.3390/ijms27031292
BibTeX
@article{Nadella2026,
author = {Nadella, Vinod and Sharma, Anu},
title = {Targeting Macrophages in Immunotherapy: The Ascent of CAR-Macrophages},
journal = {International Journal of Molecular Sciences},
year = {2026},
volume = {27},
number = {3},
pages = {1292},
doi = {10.3390/ijms27031292}
}
EUVIMED